Case report

A miner with No left lung: Extensive pulmonary destruction in delayed effective Multi-Drug-Resistant Tuberculosis treatment

Patrick D.M.C. Katoto a,b,*, Patrick Musole a, Ghislain Maheshe c, Bertrand Bamuleke a, Aime Murhula a, Patrick Balungwe d, Liliane N. Byamungu e,f

a Department of Internal Medicine, Division of Respiratory Medicine & Prof. Lurhuma Biomedical Research Laboratory, Catholic University of Bukavu, Bukavu, Democratic Republic of the Congo  
b Department of Global Health, Centre for Infectious Diseases, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa  
c Department of Medical Imaging, Provincial General Hospital of Bukavu, Catholic University of Bukavu, Bukavu, Democratic Republic of the Congo  
d Department of Otorhinolaryngology, Provincial General Hospital of Bukavu, Catholic University of Bukavu, Bukavu, Democratic Republic of the Congo  
e Department of Paediatric, Provincial General Hospital of Bukavu, Catholic University of Bukavu, Bukavu, Democratic Republic of the Congo  
f Department of Global Health, Centre for Infectious Diseases, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

ARTICLE INFO

Keywords:  
Mycobacterium tuberculosis  
Complication  
Thoracic surgery  
Democratic republic of Congo

ABSTRACT

We report a case of extensive pulmonary destruction due to delayed effective pulmonary tuberculosis (TB) treatment in an adult artisanal miner in eastern Democratic Republic of Congo. Xpert MTB/RIF was positive after his second rifampicin-susceptible TB treatment. Chest X-rays were suggestive of large cavity, fibrosis of remaining lung and air-fluid levels at the base of the destroyed lung. The patient passed away after delayed effective TB regimens. Clinicians should be aware that urgent surgical intervention is often required to prevent lethal acute respiratory failure and shock notwithstanding effective chemotherapy in such condition. Effort is needed to timely diagnose multidrug resistance TB and to implement thoracic surgery for TB in high burden countries.

1. Introduction

New confirmed cases of multidrug-resistant tuberculosis (MDR-TB) has almost doubled over the past five years and is associated with roughly one third of deaths due to antimicrobial resistance globally [1, 2]. Factors affecting prognosis, outcomes, and the risk-to-benefit ratio of MDR-TB treatment are related to Mycobacterium tuberculosis itself (mycobacterial load, drug-specific resistance profile, strain type etc.), host (HIV-coinfection, diabetes mellitus, radiologic disease burden or disease extent etc.) and national TB programme (access to effective drugs, adherence-promoting measures, social support etc.) [1]. Long delays in the initiation of treatment are a barrier to MDR-TB control [3]. Delayed effective TB treatment has been associated with progressive, extensive damage of one or both lungs [4–6]. Resolution with effective antimicrobial therapy is possible but in many cases, there is a need for an urgent surgical intervention because of life-threatening complications such as acute respiratory failure and shock that persist despite appropriate antimicrobial therapy [5,7–9]. In this report from a post conflict region in eastern Democratic Republic of Congo, a high TB, MDR and HIV-infection burden country, we describe a case of an extensive lung destruction following both patient and health-system delaying timely treatment initiation.

2. Case report

A 44-year-old artisanal digger of coltan (Niobium + Tantalum) was transferred to hospital for multi-drug-resistant tuberculosis or rifampicin-resistant tuberculosis (MDR/RR-TB) treatment. As per national guidelines, he has completed the first-line drug regimen, including 2 months of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), followed by 4 months of R and H (2RHZE/4RH). Due to persistence of symptomatology, he was retreated for failure by an 8-month regimen, including streptomycin (S) for the first 2 months (2SRHZE/1RHZE/5RHE). MDR-RR-TB was suspected as the patient persisted having fever, cough with bloodstained mucopurulent sputum a month after his second rifampicin-susceptible TB (RS-TB) treatment.

* Corresponding author. Department of Internal Medicine, Division of Respiratory Medicine & Prof. Lurhuma Biomedical Research Laboratory, Catholic University of Bukavu, Bukavu, Democratic Republic of the Congo.

E-mail addresses: katotopatrick@gmail.com, katoto.chimusa@ucbukavu.ac.cd (P.D.M.C. Katoto).

https://doi.org/10.1016/j.rmcr.2020.101234
Received 24 July 2020; Received in revised form 21 September 2020; Accepted 21 September 2020
Available online 28 September 2020
2213-0071/© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The patient’s history noted that, for four months since the first occurrence of respiratory manifestations to the first RS-TB, the patient self-medicated with cotrimoxazole and sought traditional/religious leaders help without success. On clinical examination, he presented with pyrexia, was dyspneic with reduced chest compliance, dullness on percussion with absence of tactile fremitus and majorly diminished breath sounds on the left side of the chest.

Laboratory investigations showed a leukocytosis (21.7 x 10^9 per L) with marked eosinophilia. Sputum culture showed gram-negative bacteria (non-identified). Ziehl-Neelsen test for acid-fast bacilli on different sputum samples and HIV-infection serology were negative. Xpert-MTB/RIF on sputum sample was positive. Chest x-ray showed a mosaic of lesions suggestive of a complicated PTB (Fig. 1). CT-Scan was not available in the province. Audiometry confirmed a bilateral sensorineural hearing loss (103 and 105 dB on the right and left respectively) post streptomycin ototoxicity.

In addition to MDR-TB and respiratory failure, we treated possible colonization (bacterial subsequently developed into an abscess and chronic pulmonary aspergillosis). We combined moxifloxacin (Mfx), clofazimine (Cfz), E., and Z throughout, supplemented by kanamycin (Km), prothionamide (Pro), and high dose isoniazid (Hh) during a 4-month intensive phase (4KmMfxProCfzZHaE/5MfxCfzZE) for MDR-TB short regimen. Cochlear implant, line probe assays to detect isoniazid resistance as well as mycobacterial culture were unfortunately not available for logistical reasons. Evolution was characterized by onset of severe septic status requiring “hygienic thoracic surgery” that could have not been performed in our setting. The patient passed away at the third month of hospitalization.

3. Discussion

MDR-TB is a growing serious public health problem [10]. Hereby, we present a case with both patient and system delay resulting in an extensive pulmonary destruction that is currently very difficult to manage in low resource settings. The patient received a MDR-TB treatment since in high MDR-TB, the presence of RR-TB alone may serve as a proxy for MDR-TB.

In high burden MDR-TB country, at high risk of TB persons such miners should be prioritized for easy access to Xpert testing. Unfortunately, functional point of care Xpert MTB/RIF is rare in many rural areas. Strategies to reduce system delay should include trained health workforce and scaling up diagnostic capacity with Xpert MTB/RIF at township level (where they are the most needed) and consequently accelerating decentralized MDR-TB treatment initiation centers [3]. Patient-led active tuberculosis case-finding might supplement the well-known case-finding and assists in patient delay reduction [11].

Extensive complications during MDR/RR-TB episodes are hardly managed in low-income countries and have negatively affected the quality of care and the TB treatment cost. Our case emphasizes the need for reducing both patient and diagnostic delays to improve MDR/RR-TB outcomes for special groups. This strategy might involve strengthening health education, scaling up diagnostic capacity with Xpert MTB/RIF at township level, expanding decentralization of MDR-TB treatment centers and engaging the global community for a stable chain supply in low-income countries. Furthermore, it is time for a collective thinking to address and implement the management of TB complications in the national TB programme’ guidelines.

4. Conclusion

Extensive complications during MDR/RR-TB episodes are hardly managed in low-income countries and have negatively affected the quality of care and the TB treatment cost. Our case emphasizes the need for reducing both patient and diagnostic delays to improve MDR/RR-TB outcomes for special groups. This strategy might involve strengthening health education, scaling up diagnostic capacity with Xpert MTB/RIF at township level, expanding decentralization of MDR-TB treatment centers and engaging the global community for a stable chain supply in low-income countries. Furthermore, it is time for a collective thinking to address and implement the management of TB complications in the national TB programme’ guidelines.

Contributors

We were both responsible for the diagnosis, treatment, and care of the patient. PDMCK and PM wrote the original draft of the manuscript and obtained the images. We both edited and finalized the final version. Written consent for publication was obtained from the patient’s spouse.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] K. Dheda, T. Gumbo, G. Maartens, et al., The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis, Lancet Respir Med 7 (2019) 820–826.

[2] WHO, Global tuberculosis report 2019. WHO. http://www.who.int/tb/publication s/global_report/en/ (Accessed 5 April 2020).

[3] Y. M. Htun, T. M. M. Khing, N. M. Aung, et al., Delay in treatment initiation and treatment outcomes among adult patients with multidrug-resistant tuberculosis at Yangon Regional Tuberculosis Centre, Myanmar: a retrospective study, PLoS One 13 (2018), e0209952.
[4] P.E. Palmer, Pulmonary tuberculosis—usual and unusual radiographic presentations, Semin. Roentgenol. 14 (1979) 204–243.

[5] Y.J. Ryu, J.H. Lee, E.-M. Chun, J.H. Chang, S.S. Shim, Clinical outcomes and prognostic factors in patients with tuberculous destroyed lung, published online Feb, https://www.ingentaconnect.com/content/ijtld/ijtld/2011/00000015/00000002/art00019, 2011. (Accessed 12 June 2018).

[6] E.D. Bobrowitz, D. Rodescu, H. Marcus, H. Abeles, The destroyed tuberculous lung, Scand. J. Respir. Dis. 55 (1974) 82–88.

[7] Clinical manifestations and complications of pulmonary tuberculosis - UpToDate. https://www-uptodate-com.ez.sun.ac.za/contents/clinical-manifestations-and-complications-of-pulmonary-tuberculosis?search=EXTENSIVE%20TUBERCULOSIS%20DESTRUCTION&source=search_result&selectedTitle=1-150&usage_type=default&display_rank=1. (Accessed 24 July 2020).

[8] B. Xie, Y. Yang, W. He, D. Xie, G. Jiang, Pulmonary resection in the treatment of 43 patients with well-localized, cavitary pulmonary multidrug-resistant tuberculosis in Shanghai, Interact. Cardiovasc. Thorac. Surg. 17 (2013) 455–459.

[9] J. Lopez-Contreras, J. Ris, P. Domingo, M. Puig, E. Martínez, Tuberculous pulmonary gangrene: report of a case and review, Clin. Infect. Dis. 18 (1994) 243–245.

[10] A.N.H. Bulabula, E.M. Munafiri, L.N. Kitete, et al., Prevalence and outcomes of Xpert MTB/RIF-Detected drug susceptible and resistant tuberculosis in a post-conflict region of the democratic republic of the Congo, 2012-2015, in: A62. TREATMENT OF TUBERCULOSIS, American Thoracic Society, 2017. A2112–A2112.

[11] E. Andre, O. Rusumba, C.A. Evans, et al., Patient-led active tuberculosis case-finding in the Democratic Republic of the Congo, Bull. World Health Organ. 96 (2018) 522–530.

[12] F.A. Khan, M. Rehman, P. Marcus, V. Anzeta, Pulmonary gangrene occurring as a complication of pulmonary tuberculosis, Chest 77 (1980) 76–80.

[13] K. Dheda, L. Lenders, S. Srivastava, et al., Spatial network mapping of pulmonary multidrug-resistant tuberculosis cavities using RNA sequencing, Am. J. Respir. Crit. Care Med. 200 (2019) 370–380.

[14] M.-W. Kang, H.K. Kim, Y.S. Choi, et al., Surgical treatment for multidrug-resistant and extensive drug-resistant tuberculosis, Ann. Thorac. Surg. 89 (2010) 1597–1602.